Cytek Biosciences board adopts amended and restated bylaws effective September 23, 2026

Cytek Biosciences, Inc.

Board unanimously adopted amended and restated bylaws on September 23, 2026, effective immediately; Exhibit 3.1 attached to the 8-K.
Changes include removing Rule 14a-8 prefatory clause and adding disclosure/representation requirements for stockholder proposal proponents and director nominees.
Bylaws expand chairperson authority to disregard non-compliant nominations and incorporate Rule 14a-19 universal proxy rules; add special meeting advance notice procedures.
Also update adjournment notices for virtual/remote meetings and stockholder list procedures under Delaware General Corporation Law; CEO Wenbin Jiang signed on September 29, 2026.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.